Theravance Biopharma, Inc. (NASDAQ:TBPH) is Newtyn Management LLC's 3rd Largest Position

Newtyn Management LLC increased its position in Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) by 5.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 4,757,403 shares of the biopharmaceutical company's stock after buying an additional 258,337 shares during the quarter. Theravance Biopharma accounts for approximately 7.8% of Newtyn Management LLC's holdings, making the stock its 3rd biggest holding. Newtyn Management LLC owned about 9.68% of Theravance Biopharma worth $44,767,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in the company. Geode Capital Management LLC increased its stake in shares of Theravance Biopharma by 0.6% in the fourth quarter. Geode Capital Management LLC now owns 862,802 shares of the biopharmaceutical company's stock worth $8,121,000 after buying an additional 4,823 shares during the period. D. E. Shaw & Co. Inc. increased its position in Theravance Biopharma by 9.0% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 833,943 shares of the biopharmaceutical company's stock valued at $7,847,000 after purchasing an additional 69,178 shares during the period. Dimensional Fund Advisors LP boosted its holdings in shares of Theravance Biopharma by 20.8% during the 4th quarter. Dimensional Fund Advisors LP now owns 553,713 shares of the biopharmaceutical company's stock valued at $5,211,000 after buying an additional 95,304 shares in the last quarter. Bank of America Corp DE boosted its holdings in shares of Theravance Biopharma by 2.7% during the 4th quarter. Bank of America Corp DE now owns 481,475 shares of the biopharmaceutical company's stock valued at $4,531,000 after buying an additional 12,596 shares in the last quarter. Finally, Northern Trust Corp boosted its holdings in shares of Theravance Biopharma by 1.6% during the 4th quarter. Northern Trust Corp now owns 389,980 shares of the biopharmaceutical company's stock valued at $3,670,000 after buying an additional 6,198 shares in the last quarter. 99.10% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

TBPH has been the topic of a number of analyst reports. StockNews.com upgraded shares of Theravance Biopharma from a "hold" rating to a "buy" rating in a research note on Wednesday, May 14th. HC Wainwright reissued a "buy" rating and issued a $15.00 target price on shares of Theravance Biopharma in a research report on Tuesday, February 25th. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, Theravance Biopharma presently has a consensus rating of "Hold" and an average price target of $11.33.

Insider Buying and Selling

In related news, SVP Rhonda Farnum sold 4,000 shares of the stock in a transaction that occurred on Monday, April 21st. The shares were sold at an average price of $9.00, for a total value of $36,000.00. Following the completion of the sale, the senior vice president now directly owns 370,038 shares of the company's stock, valued at approximately $3,330,342. This represents a 1.07% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 6.90% of the stock is currently owned by insiders.

Theravance Biopharma Stock Performance

Shares of NASDAQ TBPH traded up $0.05 during midday trading on Monday, hitting $9.25. 58,274 shares of the company's stock traded hands, compared to its average volume of 272,491. Theravance Biopharma, Inc. has a 1 year low of $7.44 and a 1 year high of $10.90. The stock has a market capitalization of $462.26 million, a price-to-earnings ratio of -9.15 and a beta of -0.10. The firm has a fifty day moving average of $9.16 and a 200 day moving average of $9.31.

Theravance Biopharma (NASDAQ:TBPH - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.16). The business had revenue of $15.39 million for the quarter, compared to analysts' expectations of $28.08 million. Theravance Biopharma had a negative net margin of 78.18% and a negative return on equity of 24.79%. On average, equities analysts anticipate that Theravance Biopharma, Inc. will post -1.09 earnings per share for the current year.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.